European Society of Hypertension

About: European Society of Hypertension is a other organization based out in Milan, Italy. It is known for research contribution in the topics: Blood pressure & Ambulatory blood pressure. The organization has 146 authors who have published 167 publications receiving 20150 citations.

Plasma renin activity to plasma aldosterone concentration ratio correlates with night-time and pulse pressures in essential hypertensive patients treated with angiotensin-converting enzyme inhibitors/AT1 blockers.

Abstract: Objectives:Angiotensin-converting enzyme inhibitors (ACE-I) and AT1 blockers (ARB) are commonly used antihypertensive drugs, but several factors may affect their effectiveness. We evaluated the associations between ambulatory blood pressure (BP) monitoring (ABPM) parameters and plasma renin activity

Blutdruck-Telemonitoring-unterstützte antihypertensive Therapie

Abstract: Blutdruck-Telemonitoring der selbst gemessenen Werte in der Hauslichkeit bzw. im Alltag ist geeignet, die Therapiesteuerung mittels moderner Kommunikationssysteme (Telemedizin) zu erleichtern und die Blutdruckeinstellung zu verbessern. Im Munchener Register (MART) werden Patienten mit verschiedenen Hochdruckformen und therapeutischen Problemen prospektiv dokumentiert und ausgewertet. Das Telemonitoring erfolgt taglich uber den individuell notwendigen Zeitraum mit dem Stabil-O-Graph (I. E. M. GmbH, Deutschland). Bisher sind 102 Patienten (23–92 Jahre, Durchschnittsalter 56 Jahre, 65 % Frauen) im Register erfasst: 38 mit unkontrollierter Hypertonie einschlieslich Patienten nach erfolgloser renaler Denervierung, 24 Patienten mit komplexer Medikamentenumstellung, 17 mit hypertensiver Krise bzw. Notfall, 13 Patientinnen mit Hypertonie in der Schwangerschaft und 10 ubertherapierte Patienten zur Uberwachung eines kontrollierten Auslassversuchs insbesondere nach Beendigung einer Betablockade. Das Telemonitoring wurde von 1 Woche bis uber 2 Jahre durchgefuhrt, entsprechend den individuellen Notwendigkeiten. Telemonitoring von Blutdruck und Puls aus der Hauslichkeit ist ein sehr gut geeignetes Verfahren, um die Therapiesteuerung bei verschiedenen Hochdruckformen und therapeutischen Problemen zu verbessern, und hat eine hohe Akzeptanz seitens der Patienten.

Risk stratification in hypertension: NT-proBNP and R wave in aVL lead combination better than echocardiographic left ventricular mass.

Abstract: Objectives Plasma N-terminal pro brain natriuretic peptide (NT-proBNP) and R wave in aVL lead (RaVL) have been associated with mortality in hypertension. The aim of the current study was to compare the prognostic value of their combination to that of the left ventricular mass index (LVMI) assessed by echocardiography. Methods A total of 1104 hypertensive patients who had at baseline an assessment of plasma NT-proBNP, a 12-lead ECG, and echocardiography were included. LVMI was assessable in 921 patients. After a median (interquartile range) follow-up of 8.5 (5.4-13.3) years, 110 deaths occurred, 62 of which were from a cardiovascular cause. Results Optimal thresholds of RaVL and plasma NT-proBNP to predict mortality were 0.7 mV and 150 pg/ml, respectively. A three-modality variable based on RaVL and NT-proBNP was built: 0 when none were above the threshold, 1 or 2 when only one or both were above the threshold. After adjustment for all confounders including LVMI indexed to height raised to the allometric power of 2.7 in Cox regression analysis, we observed a significant increased risk for patients having one marker above the threshold for all-cause and cardiovascular mortality [hazard ratio: 1.76; 95% confidence interval (1.08-2.86); 2.18 (1.06-4.46)] and for those having two markers above the threshold [2.76 (1.51-5.03); 3.90 (1.69-9.00)]. The prognostic value of the combination had the highest C-index (0.772 and 0.839, respectively) in comparison with LVMI (0.746 and 0.806, respectively). Conclusion Risk stratification in hypertension using the combination of NT-proBNP and RaVL is a simple method that may be considered in first line screening.